Back

Abingworth Exceeds Target on Latest Life-Sciences Fund

  • Written By: Asante Capital

U.K. life-sciences investor Abingworth said it has closed a new fund with $315 million. The vehicle, Abingworth Bioventures VII LP, exceeded its $300 million target. Placement agent Asante Capital Group helped raise the fund. Abingworth has invested in more than 145 life-sciences companies and raised 12 life-sciences funds since its founding in 1973.

READ FULL ARTICLE ON WSJ PRO

Vertex Ventures China (the ‘Firm’, ‘VVC’) closes Fund V at USD 390 million

We are pleased to announce the successful final closing of Vertex Ventures China V L.P. (the ‘Fund’) at USD 390 million. The Fund surpassed its predecessor fund size by over 40%.

Asante Capital congratulates its partner Maguar Capital on the close of a more than €235 million continuation fund transaction for HRworks

We are delighted to share that Maguar Capital Capital GmbH & Co. KG, managed by Maguar Capital, a leading B2B software investor in the DACH region, yesterday closed on the sale of its portfolio company HRworks Holding GmbH to a newly established continuation fund, Maguar Continuation Fund I GmbH & Co. KG (“Maguar CF I”).

Asante Capital congratulates its partner BPOC on establishing a $425 million continuation fund

We are delighted to announce that BPOC, a pure-play healthcare investor, announced the closing of its first continuation vehicle, a $425 million transaction co-led by investment funds affiliated with Apollo S3, Blackstone Strategic Partners and Five Arrows.
Back to top
© Asante 2023
Design by Firedog